A novel nomogram based on cardia invasion and chemotherapy to predict postoperative overall survival of gastric cancer patients

Hanjun Mo, Pengfei Li and Sunfang Jiang

Abstract

Background: We aimed to establish and externally validate a nomogram to predict the 3- and 5-year overall survival (OS) of gastric cancer (GC) patients after surgical resection.

Methods: A total of 6543 patients diagnosed with primary GC during 2004–2016 were collected from the Surveillance, Epidemiology, and End Results (SEER) database. We grouped patients diagnosed during 2004–2012 into a training set (n = 4528) and those diagnosed during 2013–2016 into an external validation set (n = 2015). A nomogram was constructed after univariate and multivariate analysis. Performance was evaluated by Harrell’s C-index, area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and calibration plot.

Results: The multivariate analysis identified age, race, location, tumor size, T stage, N stage, M stage, and chemotherapy as independent prognostic factors. In multivariate analysis, the hazard ratio (HR) of non-cardia invasion was 0.762 (P < 0.001) and that of chemotherapy was 0.556 (P < 0.001). Our nomogram was found to exhibit excellent discrimination: in the training set, Harrell’s C-index was superior to that of the 8th American Joint Committee on Cancer (AJCC) TNM classification (0.736 vs 0.699, P < 0.001); the C-index was also better in the validation set (0.748 vs 0.707, P < 0.001). The AUCs for 3- and 5-year OS were 0.806 and 0.815 in the training set and 0.775 and 0.783 in the validation set, respectively. The DCA and calibration plot of the model also shows good performance.

Conclusions: We established a well-designed nomogram to accurately predict the OS of primary GC patients after surgical resection. We also further confirmed the prognostic value of cardia invasion and chemotherapy in predicting the survival rate of GC patients.

Keywords: Nomogram, Gastric cancer, Overall survival, SEER
Introduction
Gastric cancer (GC) remains the fifth most common cancer and the third main cause of cancer-related death, following lung cancer and colorectal cancer in both sexes [1]. More than one million people are diagnosed with GC annually, and the death toll is close to 800,000 [1]. The incidence among males is 2- to 3-fold higher than that among females (32.1 vs 13.2, per 100,000) in East Asia, whereas the rate in North America is generally low [1].

GC can be classified as cardia and non-cardia invasion, which have different epidemiology and causes [2, 3]. The incidence of non-cardia GC has declined over the past 30 years; however, cardia GC rates have remained stable or even increased [2, 4, 5]. The poor prognosis of cardia invasion compared to non-cardia has been reported [6, 7], but whether cardia invasion is an independent prognostic factor remains unknown.

Surgery is still the primary treatment to advanced GC [8], in which D2 lymphadenectomy has been widely carried out in Asia [9, 10]. A study from Japan of the 118,367 patients after surgical resection showed the 5-year overall survival (OS) rate is 71.1% [11]. However, recurrence occurs in approximately 20–50% of all patients after surgery [12]. Therefore, identifying prognostic factors is indispensable in choosing treatment methods and surveillance strategies.

A nomogram is one of the useful predictive tools for cancer due to its accuracy, practicability, and good discrimination [13]. It can quantify individual’s survival rate in graphic form and has been used for many tumors [14–16]. The classic nomogram for GC is the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram created in 2003 [17]. Compared with the traditional staging system—the American Joint Committee on Cancer (AJCC) TNM classification, a nomogram incorporates more demographic and clinicopathologic factors into the model.

The 8th AJCC staging system was effective in 2018, but few studies have compared nomograms with this new edition. In addition, the role of chemotherapy in the prognosis of GC has been mentioned, but no nomograms have included chemotherapy as a variable to date [9, 18]. Finally, most of the established nomograms for GC are complicated or internally validated, or they have a small training set [9, 12, 18–20]. Consequently, we aim to establish and externally validate a relatively simple, generalized nomogram to predict the overall survival (OS) of primary GC patients after surgical resection. We hope to determine the value of identifying GC as cardia or non-cardia invasion while exploring the role of adjuvant chemotherapy. The performance of the nomogram is also compared with the AJCC 8th staging system.

Materials and methods
Patients and data set
Data from patients diagnosed with primary GC during 2004–2016 were collected from the Surveillance, Epidemiology, and End Results (SEER) 18 Regs Custom Data Set (with additional treatment fields, Nov 2018 Sub), covering 27.8% of the US population [21]. The identification of GC patients was based on ICD-O-3/WHO 2008 histology codes. TNM staging was recoded according to the 8th AJCC TNM classification. The inclusion criteria were as follows: primary GC after surgical resection; no other malignancies; positive histology affirmation; no preoperative radiotherapy; more than 16 examined lymph nodes (LN); and complete clinical data without missing values. The detailed enrollment process is presented in Fig. 1. Types of overlapping lesions and unspecified lesions were excluded. Finally, a total of 6543 cases were included in our study. We grouped them into a training set (n = 4528) and an external validation set (n = 2015) according to the year of diagnosis (2004–2012 and 2013–2016, respectively). Comparisons of demographic and clinicopathologic variables between the training and validation sets were generated using the “table1” function in R software.

Construction of the nomogram
The cutoff values of continuous variables were determined using X-tile software designed by the Yale School of Medicine and our clinical experience. We divided patients into two groups according to their age (< 70 or ≥ 70 years) and into three groups according to the tumor size (< 2 cm, 2–10 cm, or ≥ 10 cm/diffuse). In variable of race, “other” included American Indian/AK Native and Asian/Pacific Islander. The SEER database classifies tumor histology (grade) into 4 groups: well differentiated (grade I), moderately differentiated (grade II), poorly differentiated (grade III), and undifferentiated/anaplastic (grade IV). We integrated poorly differentiated and undifferentiated/anaplastic tumors into a single group (named as “Poorly”) [21]. Location was further stratified into cardia and non-cardia invasion (including fundus, body, antrum and pylorus, lesser and greater curvature).

After univariate and multivariate analyses, independent prognostic factors were identified by the forward stepwise selection method. The proportional hazards (PH) assumption was examined before the multivariate analysis to ensure that the variables fitted the PH assumption. In the univariate analysis, the variables were further analyzed with the Cox proportional hazards (PH) regression model when P < 0.1. A nomogram was then constructed to predict the 3- and 5-year OS for primary GC patients after surgery. Kaplan-Meier (KM) survival curves were constructed and compared with the log-rank test.
**Nomogram performance**

The performance of our nomogram was evaluated by discrimination and calibration. Discrimination was evaluated using Harrell’s C-index. The principle of the C-index has been described by Han et al. [9]. The $P$-value comparison of our nomogram with the AJCC staging system was achieved using the “compareC” function in R. The prediction was further evaluated by the area under the receiver operating characteristic curve (AUC) and the net benefit of decision curve analysis (DCA). Calibration was carried out by comparing the means of the nomogram-predicted survival rate with the actual OS measured by the KM method. Bootstraps were set to 1000 reiterations. Predicted total points were added as a new variable to the established nomogram in order to achieve external validation. Calibration plots of 3- and 5-year survival in the training set and 3-year survival in the validation set were constructed.

**Statistical analysis**

Statistical analysis was performed using SPSS version 22.0 (SPSS, Chicago, IL, USA) and R 4.0.1 via rms, survival, table1, compareC, and ggplot2 packages. All tests were two-sided, and $P$-value < 0.05 was considered statistically significant. This study did not require local ethics approval.

**Results**

**Patient characteristics**

Demographic and clinicopathologic characteristics are presented in Table 1. The median age at diagnosis in both sets was 66 years, and male patients were the majority (60.5% and 61.3% in the training and validation sets).
| Variable                      | Training set (n = 4528) |   | Validation set (n = 2015) |   |
|-------------------------------|-------------------------|---|---------------------------|---|
|                              | n                        | % | n                        | % |
| Age (years)                  |                          |   |                           |   |
| Median (range)               | 66 (55–75)               |   | 66 (56–74)                |   |
| < 70                         | 2748                     | 60.7 | 1226                     | 60.8 |
| ≥ 70                         | 1780                     | 39.3 | 789                       | 39.2 |
| Sex                          |                          |   |                           |   |
| Male                         | 2741                     | 60.5 | 1236                     | 61.3 |
| Female                       | 1787                     | 39.5 | 779                       | 38.7 |
| Race                         |                          |   |                           |   |
| White                        | 2787                     | 61.6 | 1156                     | 57.4 |
| Black                        | 568                      | 12.5 | 263                      | 13.1 |
| Other                        | 1173                     | 25.9 | 596                      | 29.6 |
| Location                     |                          |   |                           |   |
| Cardia                       | 1135                     | 25.1 | 364                      | 18.1 |
| Non-cardia                   | 3393                     | 74.9 | 1651                     | 81.9 |
| Grade (histology)            |                          |   |                           |   |
| Well                         | 155                      | 3.4 | 102                      | 5.1 |
| Moderately                   | 1106                     | 24.4 | 483                      | 24.0 |
| Poorly                       | 3267                     | 72.2 | 1430                     | 71.0 |
| AJCC 8th Stage               |                          |   |                           |   |
| I                            | 1109                     | 24.5 | 517                      | 25.7 |
| II                           | 1513                     | 33.4 | 501                      | 24.9 |
| III                          | 1401                     | 30.9 | 846                      | 42.0 |
| IV                           | 505                      | 11.2 | 151                      | 7.5 |
| T stage                      |                          |   |                           |   |
| T1                           | 736                      | 16.3 | 448                      | 22.2 |
| T2                           | 1676                     | 37.0 | 251                      | 12.5 |
| T3                           | 1407                     | 31.1 | 727                      | 36.1 |
| T4                           | 709                      | 15.7 | 589                      | 29.2 |
| N stage                      |                          |   |                           |   |
| N0                           | 1274                     | 28.1 | 717                      | 35.6 |
| N1                           | 1176                     | 26.0 | 359                      | 17.8 |
| N2                           | 1054                     | 23.3 | 353                      | 17.5 |
| N3                           | 1024                     | 22.6 | 586                      | 29.1 |
| M stage                      |                          |   |                           |   |
| M0                           | 4023                     | 88.8 | 1865                     | 92.6 |
| M1                           | 505                      | 11.2 | 150                      | 7.4 |
| Tumor size (cm)              |                          |   |                           |   |
| < 2                          | 476                      | 10.5 | 328                      | 16.3 |
| 2–10                         | 3620                     | 79.9 | 1532                     | 76.0 |
| ≥ 10/diffuse                 | 432                      | 9.5 | 155                      | 7.7 |
| Examined LNs (No.)           |                          |   |                           |   |
| Median (range)               | 23 (19–31)               |   | 24 (19–33)               |   |
| Radiation                    |                          |   |                           |   |
| No radiation or surgery      | 3029                     | 66.9 | 1526                     | 75.7 |
| Yes                          | 1499                     | 33.1 | 489                      | 24.3 |
| Chemotherapy                 |                          |   |                           |   |
| No/unknown                   | 2167                     | 47.9 | 873                      | 43.3 |
| Yes                          | 2361                     | 52.1 | 1142                     | 56.7 |

LN lymph node, AJCC American Joint Committee on Cancer
sets, respectively). Cardia GC accounted for 25.1% of the whole GC population in the training set. Most of the patients (72.2% and 71.0%, respectively) had poorly differentiated disease. The median numbers of examined LNs were 23 (range, 19–31) and 24 (range, 19–33) in the training and validation sets, respectively. 33.1% of the patients received radiotherapy, and 52.1% received chemotherapy in the training set.

### Analysis and development of the nomogram

Selected variables and hazard ratios (HRs) after univariate and multivariate analyses are listed in Table 2. We

| Variable         | Univariable analysis | Multivariable analysis |
|------------------|----------------------|------------------------|
|                  | HR 95% CI P-value    | HR 95% CI P-value      |
| Age, years       |                      |                        |
| < 70             | Ref                  | Ref                    |
| ≥ 70             | 1.526 1.419–1.642 < 0.001 | 1.671 1.546–1.806 < 0.001 |
| Sex              |                      |                        |
| Male             | Ref                  | Ref                    |
| Female           | 0.973 0.903–1.049 0.476 |                      |
| Race             |                      |                        |
| White            | Ref                  | Ref                    |
| Black            | 1.043 0.934–1.163 0.456 | 1.079 0.965–1.207 0.183 |
| Other            | 0.806 0.738–0.880 < 0.001 | 0.857 0.783–0.939 0.001 |
| Location         |                      |                        |
| Cardia           | Ref                  | Ref                    |
| Non-cardia       | 0.906 0.835–0.983 0.018 | 0.762 0.699–0.831 < 0.001 |
| Grade            |                      |                        |
| Well             | Ref                  | Ref                    |
| Moderately       | 1.515 1.182–1.942 0.001 | 0.972 0.756–1.249 0.824 |
| Poorly           | 2.064 1.624–2.623 < 0.001 | 1.153 0.902–1.474 0.257 |
| T stage          |                      |                        |
| T1               | Ref                  | Ref                    |
| T2               | 2.903 2.515–3.349 < 0.001 | 2.04 1.741–2.389 < 0.001 |
| T3               | 3.896 3.371–4.504 < 0.001 | 2.265 1.919–2.674 < 0.001 |
| T4               | 5.31 4.547–6.201 < 0.001 | 2.683 2.242–3.210 < 0.001 |
| N stage          |                      |                        |
| N0               | Ref                  | Ref                    |
| N1               | 2.051 1.828–2.302 < 0.001 | 1.981 1.749–2.243 < 0.001 |
| N2               | 3.527 3.147–3.952 < 0.001 | 3.308 2.912–3.758 < 0.001 |
| N3               | 5.446 4.861–6.102 < 0.001 | 4.431 3.876–5.065 < 0.001 |
| M stage          |                      |                        |
| M0               | Ref                  | Ref                    |
| M1               | 2.891 2.611–3.200 < 0.001 | 1.888 1.698–2.099 < 0.001 |
| Tumor size, mm   |                      |                        |
| < 2              | Ref                  | Ref                    |
| ≥ 2–10           | 2.477 2.122–2.892 < 0.001 | 1.158 0.980–1.369 0.085 |
| ≥ 10/diffuse     | 4.632 3.861–5.558 < 0.001 | 1.57 1.289–1.913 < 0.001 |
| Chemotherapy     |                      |                        |
| No/unknown       | Ref                  | Ref                    |
| Yes              | 0.936 0.870–1.006 0.073 | 0.556 0.513–0.602 < 0.001 |

*HR* hazard ratio, CI confidence interval, Ref reference
identified age, race, location, T stage, N stage, M stage, tumor size, and chemotherapy as independent prognostic factors associated with OS for GC patients. Due to a lack of significance, sex was excluded from the Cox PH regression model (HR, 0.973; 95% CI, 0.903–1.049).

Among the patients included in our research, HRs were found to be significantly higher for individuals who had the following characteristics: older than 70, male, black, cardia invasion, poorly differentiated disease, deeper invasion, more lymph node (LN) metastasis, distant metastasis, larger tumor size, and without chemotherapy. Of note, after adjustment for the multivariate analysis, the HR for location was 0.762 (95% CI, 0.699–0.831, $P < 0.001$), indicating that non-cardia invasion is an independent protective factor for GC prognosis. There are two distinct discrepancies between the univariate and multivariate analyses. Although grade was statistically significant in the univariate analysis, it seemed to be nonsignificant when adjusted by the multivariate model. Considering that grade represents histologic differentiation and is of clinical value, we still
Fig. 3 Kaplan-Meier survival curves of chemotherapy (A) and chemotherapy after adjustment (B).

Fig. 4 Nomogram predicting 3- and 5-year OS after surgical resection of GC. OS, overall survival; GC, gastric cancer; Other, American Indian/AK Native and Asian/Pacific Islander; Well, well differentiated; Moderately, moderately differentiated; Poorly, poorly differentiated and undifferentiated/anaplastic.
included it in the model. For chemotherapy, no statistically significant difference was observed in the univariate analysis (HR, 0.936; 95% CI, 0.870–1.006, \( P = 0.073 \)). However, in the multivariate analysis, the difference became significant (HR, 0.556; 95% CI, 0.513–0.602, \( P < 0.001 \)). The KM survival curves of select factors are shown in Figs. 2 and 3. In each panel of Fig. 2, the curves show good prognostic stratification for selected variables. As shown in Fig. 3, postoperative chemotherapy significantly prolonged patient survival after the adjustment for the Cox PH model.

The nomogram used to predict 3- and 5-year OS is shown in Fig. 4. From Fig. 4, we can see that \( N \) stage accounts for a large proportion of the total scores, indicating that the number of metastatic LNs is the most critical prognostic factor for GC. Patients with cardia invasion receive nearly 20 points, and those who do not undergo chemotherapy receive approximately 40 points.

### Table 3 C-indexes for the nomogram and the AJCC 8th staging system in GC patients

| OS       | Training set | Validation set |
|----------|--------------|----------------|
|          | C-index (95% CI) | \( P \)-value | C-index (95% CI) | \( P \)-value |
| Nomogram | 0.736 (0.726–0.746) | \( < 0.001 \) | 0.748 (0.726–0.770) | \( < 0.001 \) |
| 8th AJCC stage | 0.699 (0.689–0.709) | \( < 0.001 \) | 0.707 (0.684–0.730) | \( < 0.001 \) |

AJCC American Joint Committee on Cancer, GC gastric cancer, OS overall survival, CI confidence interval

The performance of the nomogram

In the training set (Table 3), the C-index was 0.736 (95% CI, 0.726–0.746), which was superior to that of the 8th

![Fig. 5 Receiver operating characteristic (ROC) curves predicting OS.](image-url)
AJCC TNM classification (C-index, 0.699; 95% CI, 0.689–0.709, \( P < 0.001 \)). In the validation set, the C-index was also better (0.748 vs 0.707; 95% CI, 0.726–0.770 vs 0.684–0.730, \( P < 0.001 \)). In addition, the AUCs of the nomogram exhibited great predictive ability in both the training and validation sets, with AUCs of 0.806 and 0.815 at 3 years and 5 years in the training set, respectively (Fig. 5A, B). In the validation set (Fig. 5C, D), the AUCs were only slightly reduced (0.775 and 0.783 for 3- and 5-year OS, respectively). The DCA results further demonstrated the good performance of our nomogram (Fig. 6). Regardless of the training (Fig. 6A, C) or validation set (Fig. 6B, D), our nomogram had a larger net benefit than the AJCC TNM classification. This favorable effect remains across a threshold probability of 0.05 to 0.45 for 3 years and 0.6 for 5 years.

The calibration plots also showed good agreement for the nomogram-predicted 3-, 5-year survival in the training set and 3-year survival in the validation set (Fig. 7). The 5-year curve in the validation set cannot be constructed because of inadequate follow-up time (patients were diagnosed during 2013–2016). The diagonal line represents the ideal situation, and we can see that the predicted survival corresponds closely with the actual OS.

**Discussion**

In the current study, we developed and externally validated a nomogram to predict 3- and 5-year OS for primary GC patients after surgical resection. We identified age, race, location, tumor size, T stage, N stage, M stage, and chemotherapy as independent prognostic factors, among which the number of metastatic LNs held the most weight [22]. Compared with the 8th AJCC TNM classification, our nomogram performed better in both the training and external validation sets.

Some nomograms classified GC location into the upper, middle, and lower third [9, 18]. In this study, we classified GC according to cardia invasion or no cardia invasion (the survival curves of the middle third and lower third were similar in our cohort; data not shown). As a result, we found that cardia GC had a worse
Fig. 7 Calibration curves predicting overall survival. A. 3-year in the training set, B. 5-year in the training set, and C. 3-year in the validation set. The x-axis represents nomogram-predicted survival; the y-axis represents actual survival and 95% confidence intervals (CIs) measured by Kaplan-Meier analysis.
prognosis than non-cardia GC ($P < 0.001$). Our finding is consistent with a systematic review, which found that patients with upper third GC had significantly increased all-cause mortality [23]. And when the gastroesophageal junction (GEJ) was excluded, the prognosis of pure cardia GC was even worse. Our data also showed that sex was not an independent prognostic factor, which was inconsistent with previous findings [9, 12, 17, 18, 24]. Although males and females differed in terms of incidence rate, their prognoses appeared to be similar.

Previously, Kim et al. found that age had nonlinear effects on HR [12]. Another study also found that patients older than 70 years had the lowest 5-year OS, compared with younger and middle-aged patients [25]. Their results were consistent with our analysis using X-tile, so we chose to convert age into a categorical variable at 70. Although grade is closely associated with malignant behavior and distant metastasis, it did not seem to be an independent factor in our study. Therefore, when we performed multivariate analysis, the $P$-value became insignificant.

Another discrepancy in this study pertains to chemotherapy [26]. Recent studies have proven that adjuvant chemotherapy after surgery could benefit patients in terms of survival probability [27]. A meta-analysis showed that compared with surgery alone, fluorouracil-based postoperative adjuvant chemotherapy significantly reduced the mortality of GC patients [28]. Another phase III randomized controlled trial (RCT) revealed that chemotherapy using capecitabine plus oxaliplatin for half a year after D2 gastrectomy improved the 3-year disease-free survival of GC compared with surgery alone (74% vs 59%, HR 0.56, $P < 0.001$) [29]. The results of our multivariate analysis further demonstrated that chemotherapy acted as a protective factor against poor outcomes (Fig. 3). We believe that chemotherapy did not show statistical significance in the univariate analysis was largely due to some confounding factors, such as age, location, or TNM staging. To the best of our knowledge, we are the first to finally include chemotherapy in the nomogram construction of GC.

Consistent with most previous studies, we excluded patients with fewer than 16 examined LNs [9]. This helps to ensure surgical quality and prevent the stage migration effect [9, 30]. In our study, the median examined LN numbers were 23 and 24 in the training and validation sets, respectively.

Quite a few studies used a randomly assigned (data-splitting) method to create a validation set [9, 19, 20]. However, theoretically, this method accounts as an internal validation rather than an external validation, leading to sample wasting as well as insufficient power for evaluation. In contrast, our external validation set was established according to the year of diagnosis (training set, 2004–2012; validation set, 2013–2016), which would produce a more convincing result.

Notably, 655 patients had distant metastasis (M1) but underwent surgery. Among them, 58.6% (384/655) received chemotherapy and 15.1% (99/655) received radiotherapy. A growing number of studies have shown that patients with unresectable stage IV GC can achieve good survival outcomes if they undergo radical gastrectomy after responding to several combined chemotherapy regimens [31]. This novel strategy is called conversion surgery, a treatment approach in which initially unresectable tumors become curable after chemotherapy response. If R0 resection is achieved, conversion surgery can significantly improve the patient survival rate [31]. Therefore, we did not exclude such patients and hope that our nomogram can be used with these patients to predict OS after surgery. Nevertheless, this concept is still controversial, and current cancer guidelines do not recommend surgery for stage IV patients.

There are some striking strengths in our study. First, we used the SEER database, a standardized and relatively comprehensive database with a large sample size. Data from 2004 were collected, and more than 6000 patients were ultimately included in our study. Second, to the best of our knowledge, we are the first to classify GC according to cardia/non-cardia invasion in a nomogram and found good discrimination in survival outcomes. We are also the first to finally include chemotherapy in the nomogram for GC as an independent prognostic factor. Third, our nomogram is based on the existing 8th AJCC staging system, which makes the nomogram widely available and highly convenient for clinical application.

Our study also has some limitations that should be noted. First, patients who did not receive chemotherapy and those with missing information were included in the SEER database, which added difficulty in determining the value of chemotherapy. As a result, the actual role of chemotherapy in patients’ prognosis could have been underestimated. Second, we did not further divide T4 and N3 stages in our results because 893 cases had T4 or N3 stage but lacked specific details. This may have sacrificed some precision but simplified the model. Finally, some novel biomarkers were reported to be useful in predicting prognosis of GC, such as differential gene expression, which will be tested in future studies [32–35].

Conclusions

In summary, we established and externally validated an elaborate nomogram to predict 3- and 5-year OS for primary GC after surgical resection. We believe that our nomogram can achieve accurate predictions among Western populations. Future studies are needed to further evaluate its performance and extend its applicability.
Abbreviations
SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; GC: Gastric cancer; OS: Overall survival; HR: Hazard ratio; LN: Lymph node; TNM: Tumor-node-metastasis; ROC: Receiver operating characteristic; AUC: Area under receiver operating charater curve; DCA: Decision curve analysis

Acknowledgements
The authors would like to thank the Surveillance, Epidemiology, and End Results (SEER) Research Database (1975–2016) of National Cancer Institution. We acknowledged the funding support by the Program for Shanghai Outstanding Medical Academic Leader (2019LJ15) and Scientific Research Project of Shanghai Science and Technology Commission (17ZR1404900).

Authors’ contributions
Conception and design: HM, PL, and SJ. Data collection, analysis, and interpretation: HM and PL. Manuscript writing: HM. Review and editing: HM, PL, and SJ. Administrative support: SJ. The authors read and approved the final manuscript.

Funding
The study was supported by the Program for Shanghai Outstanding Medical Academic Leader (2019LJ15) and Scientific Research Project of Shanghai Science and Technology Commission (17ZR1404900).

Availability of data and materials
The datasets supporting our conclusion can be acquired from SEER database (https://github.com/wdxmo/nomogram/find/main). All R codes used in this study can be accessed via Github (https://github.com/wdxmo/nomogram/find/main).

Declarations

Ethics approval and consent to participate
All the data were accessed from the public SEER database and no ethical approval was required.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of General Practice, Zhongshan Hospital, Fudan University, 111 Yixueyuan Road, Shanghai 200032, China. 2Department of General Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China. 3Health Management Center, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

Received: 22 April 2021 Accepted: 10 August 2021
Published online: 28 August 2021

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492
2. Karmi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(5):700–13. https://doi.org/10.1158/1055-9965.EPI-13-1057
3. Gupta S, Tao L, Murphy JD, Camargo MC, Oren E, Valasek MA, et al. Race/ethnicity, socioeconomic status-, and anatomic subtype-specific risks for gastric cancer. Gastroenterology. 2019;156:59–62.e4
4. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric carci carcinomas. Journal of the National Cancer Institute. 2004;96(18):1383–7. https://doi.org/10.1093/jnci/djh365
5. Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. Jama. 2010;303(17):1723–8. https://doi.org/10.1001/jama.2010.496
6. Kim YJ, Chung WC, Cho IH, Kim J, Kim S. Prognostic effect of different etiologies in patients with gastric cardia cancer. Medicine. 2019;98(50): e19397. https://doi.org/10.1097/MD.0000000000018937
7. Zhao J, Zhao J, Du F, Zhang Y, Sheng G, Zhu H, et al. Cardia and non-cardia gastric cancer have similar stage-for-stage prognoses after R0 resection: a large-scale, multicenter study in China. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2016;20(4):700–7. https://doi.org/10.1007/s11605-016-3089-z
8. Wu SY, Ho MH, Chang HM, Hsu KS, Yu JC. Chan DC. Long-term oncologic result of laparoscopic versus open gastrectomy for gastric cancer: a propensity score matching analysis. World journal of surgical oncology. 2021;19:101.
9. Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(31):3834–40. https://doi.org/10.1200/JCO.2012.41.8343
10. Wang Y, Wang Y, Wu W, Lu K, An T, Jiang J. Laparoscopic gastrectomy plus D2 lymphadenectomy is as effective as open surgery in terms of long-term survival: a single-institution study on gastric cancer. World journal of surgical oncology. 2021;19(1):102. https://doi.org/10.1186/s12957-021-02218-1
11. Katal H, Ishikawa T, Akazawa K, Ioseb Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018;21(1):144–54. https://doi.org/10.1007/s12957-017-0716-7
12. Kim Y, Spolverato G, Ejar A, Squires MH, Poultsides G, Fields RC, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Annals of surgical oncology. 2015;22(6):1828–35. https://doi.org/10.1245/s10434-014-4230-4
13. Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K, et al. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World journal of surgical oncology. 2021;19(1):173. https://doi.org/10.1186/s12957-021-02386-3
14. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(9):1186–95. https://doi.org/10.1200/JCO.2012.41.5984
15. Rudloff U, Jacks LM, Goldberg J, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(23):3762–9. https://doi.org/10.1200/JCO.2009.26.8847
16. Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(8):861–9. https://doi.org/10.1200/JCO.2014.65.6661
17. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(19):3647–50. https://doi.org/10.1200/JCO.2003.01.240
18. Hirabayashi S, Kosugi S, Iseobe Y, Nashimoto A, Oda I, Hayashi K, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2014;25(6):1179–89. https://doi.org/10.1093/annonc/mdu128
19. Yu C, Zhang Y. Development and validation of prognostic nomogram for young patients with gastric cancer. Annals of translational medicine. 2019;7(22):641. https://doi.org/10.21037/atm.2019.10.77
20. Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric cancer : official journal of the
21. Hu P, Bai J, Liu M, Xue J, Chen T, Li R, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2020;23:591–9.

22. Chen L, Yue C, Li G, Ming X, Gu R, Wen X, et al. Clinicopathological features and risk factors analysis of lymph node metastasis and long-term prognosis in patients with synchronous multiple gastric cancer. World journal of surgical oncology. 2021;19(1):20. https://doi.org/10.1186/s12957-021-02130-8.

23. Petrilli F, Ghidini M, Barni S, Stecca Nella F, Sgroi G, Passalacqua R, et al. Prognostic role of primary tumor location in non-metastatic gastric cancer: a systematic review and meta-analysis of 50 studies. Annals of surgical oncology. 2017;24(9):2655–68. https://doi.org/10.1245/s10434-017-5832-4.

24. Zheng ZF, Lu J, Wang W, Desiderio J, Li P, Xie JW, et al. Development and external validation of a simplified nomogram predicting individual survival after R0 resection for gastric cancer: an international, multicenter study. Annals of surgical oncology. 2018;25(8):2383–90. https://doi.org/10.1245/s10434-018-6551-1.

25. Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, et al. Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years. World journal of gastroenterology. 2013;19(39):6568–78. https://doi.org/10.3748/wjg.v19.i39.6568.

26. Jiang L, Na Z, Ye X, Kang W, Yu J. Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. World journal of surgical oncology. 2021;19(1):44. https://doi.org/10.1186/s12957-021-02157-x.

27. Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Current treatment options in oncology. 2013;14(3):311–20. https://doi.org/10.1007/s11864-013-0238-4.

28. Paolelli X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37. https://doi.org/10.1001/jama.2010.534.

29. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012;379:315-21.

30. Kong SH, Lee HI, Ahn HS, Kim JW, Kim WH, Lee KU, et al. Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Annals of surgery. 2012;255(1):50–8. https://doi.org/10.1097/SLA.0b013e31821d4d75.

31. Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, et al. Conversion surgery for stage IV gastric cancer. Frontiers in oncology. 2019;9:1158. https://doi.org/10.3389/fonc.2019.01158.

32. Matsunaga T, Sato H, Muyauchi W, Shishido Y, Miyatani K, Murakami Y, et al. Impact of skeletal muscle mass in patients with recurrent gastric cancer. World journal of surgical oncology. 2021;19(1):170. https://doi.org/10.1186/s12957-021-02283-6.

33. Cao F, Hu Y, Chen Z, Han W, Lu W, Xu J, et al. Circulating long noncoding RNAs as potential biomarkers for stomach cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2021;19(1):89. https://doi.org/10.1186/s12957-021-02194-6.

34. Wu J, Wang X, Wang N, Ma L, Xie X, Zhang H, et al. Identification of novel antioxidant gene signature to predict the prognosis of patients with gastric cancer. World journal of surgical oncology. 2021;19(1):219. https://doi.org/10.1186/s12957-021-02328-w.

35. Song W, Bai Y, Zhu J, Zeng F, Yang C, Hu B, et al. A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer. World journal of surgical oncology. 2021;19(1):216. https://doi.org/10.1186/s12957-021-02329-9.